Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 4/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | RAD52 | P43351 | 1/20 | 0.37 |
| ▸ | GFER | P55789 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | DRD3 | P35462 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10161167 | 0.93 | KMT2A (0.43) | DRD2KMT2ASLC18A3KDM4EGAA | |
| SCHEMBL10162738 | 0.83 | KMT2A (0.46) | DRD2KMT2AKDM4EGAAMAPT | |
| SCHEMBL10162449 | 0.83 | GAA (0.56) | DRD2KMT2AKDM4EGAAMAPT | |
| SCHEMBL10162628 | 0.83 | KMT2A (0.46) | DRD2KMT2AKDM4EGAAMAPT | |
| SCHEMBL10163589 | 0.82 | KMT2A (0.43) | DRD2KMT2ASLC18A3KDM4EGAA | |
| SCHEMBL10162843 | 0.82 | KMT2A (0.44) | DRD2KMT2AKDM4EGAAMAPT | |
| SCHEMBL10161329 | 0.81 | CHRNA7 (0.60) | DRD2KMT2ASLC18A3KDM4EGAA | |
| SCHEMBL10162465 | 0.81 | KMT2A (0.46) | DRD2KMT2AKDM4EGAAMAPT | |
| SCHEMBL10163591 | 0.80 | KMT2A (0.41) | DRD2KMT2ASLC18A3KDM4EGAA | |
| SCHEMBL10161180 | 0.79 | ESR1 (0.45) | DRD2KMT2AKDM4EGAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120165320-A1 | NOVEL AZABICYCLOHEXANES | PANACEA BIOTEC LTD. (IN) | 2012-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165320-A1 | NOVEL AZABICYCLOHEXANES | CYP3A43, UGT1A1, CYP3A4 | DRD2 834/4885KMT2A 3935/4885SLC18A3 1584/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.